Research Article

Influence of Geographical and Seasonal Variations on Carbazole Alkaloids Distribution in *Murraya koenigii*: Deciding Factor of Its *In Vitro* and *In Vivo* Efficacies against Cancer Cells

Eswara Murali Satyavarapu®, Prasun Kumar Sinha®, and Chitra Mandal®

Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, 4, Raja S.C. Mallick Road, Kolkata 700032, India

Correspondence should be addressed to Chitra Mandal; chitra_mandal@yahoo.com

Received 7 June 2019; Accepted 29 August 2019; Published 11 February 2020

Academic Editor: Claude Prigent

Copyright © 2020 Eswara Murali Satyavarapu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Murraya koenigii* is a well-known Indian medicinal herb, and a carbazole alkaloid (mahanine) from this plant causes apoptosis in cancer cells. Here, we investigated how seasonal and geographical variations influence carbazole alkaloids composition and medicinal property of this plant against cancer cells *in vitro* and *in vivo*. Leaflets were collected from various places in different seasons for three years. A mahanine-enriched fraction (MEF) was prepared in two steps using ethanol and water. The best plant was selected based on the highest percent of mahanine. MEF prepared from leaflets of nine different locations showed a different concentration of identified markers (mahanine, mahanimbine, and koenimbine) which exhibited differential reduced metabolic activity against ovarian cancer, mahanine being the best. Our systematic study revealed that mahanine content was highest during September–December. Interestingly, MEF from southern part (tropical zone) exhibited 43 ± 2.5% mahanine compared to 2.7 ± 1.3% in northeastern part (subtropical zone) with five fold higher activity against PA1. Moreover, MEF reduced metabolic activity of sixteen cancer cell lines from nine different origins and significantly reduced tumor mass in lung and ovarian cancer xenograft models. Taken together, this is the first report demonstrating the marker’s content in these leaflets is highly dependent on location/season. A positive correlation between biological activity and mahanine concentration was established in MEF. Such a comprehensive study suggests that the selection of location and suitable season for collection of any plant materials with biologically active stable markers in sufficient quantity play a decisive role in determining the fate of their medicinal property.

1. Introduction

Natural products, especially from plants, are important medicinal source for many diseases as documented in *Charaka Samhita*, a comprehensive text on ancient Indian medicine written during 200–400 B.C., known as “Encyclopedia of Ayurveda” [1]. India is considered to be the botanical garden of the world. A wide variety of plants with an array of medicinal properties has been reported [2]. However, the medicinal value of these plants depends upon several ecological factors which include climatic factors like rainfall, atmospheric humidity, wind, gases, temperature, and light; physiographic factors (altitude and sunlight); and biotic and abiotic factors (soil microorganisms and nutrients) [3]. Moreover, such ecological factors varied based on different seasons and diverse geographical regions. Therefore, it is worthwhile to prepare a detailed document for the optimization of the conditions for the collection of plant material and in-depth investigation for the best utilization of such herbal product for a specific disease.

Accordingly, we have carefully selected an edible plant, *Murraya koenigii* (L.) Spreng, commonly called as “curry leaves” or “Kari patta or Karuveppilai or Karivepaku” abundantly available throughout India, for such documentation. This herb belongs to the family Rutaceae, leaves are pinnate, with 11–21 leaflets, and each leaflet is 2–4 cm
long and 1–2 cm broad. This plant has been reported for its traditional uses like diarrhea, indigestion, and nausea in Charaka Samhita [1]. In the last ten years, we have isolated and extensively characterized a biologically active carbazole alkaloid (mahanie) from the leaflets of this plant and established its anticancer activity against different cancer cells with various mutations [4]. Our extensive study also ascertained its role in controlling several cell survival pathways in leukemia, pancreatic, ovarian, glioblastoma, cervical, and colon cancers. We also observed that mahanie is a pro-oxidant molecule. It induced death receptor-mediated apoptosis in leukemia, acts as mTORC1/2 inhibitor in glioblastoma multiform [5] and regulation of hedgehog pathway [6] and, acts as Hsp90 inhibitor in pancreatic [7] and enhanced tumor suppressor proteins in colon cancers, inhibited autophagy and LC3-mediated anoikis in ovarian cancer [8]. Additionally, it showed a good synergistic effect with clinically approved drugs both in colon and cervical cancers. It also exhibited antileishmanial activity through immunomodulation [9].

Accordingly, we aimed to prepare a mahanie-enriched fraction (MEF) from Murraya koenigii leaflets. In search of the highest mahanie-containing plant, we performed an elaborate, systemic detailed comparative study to understand the relationship of seasonal and geographical variations of other molecules present in MEF including mahanie in the leaflets of M. koenigii and compared their biological activities. Accordingly, we have collected the leaflets from all over India having different climatic conditions, altitude, and sunlight and soil properties throughout the year.

Here, we are reporting a two-step protocol for the preparation of MEFs using only two edible solvents from leaflets collected during different seasons throughout India. Next, we identified and characterized three carbazole alkaloids (mahanie, mahanimbine, and koenimbine) from MEF and compared their reduced metabolic activity against two representative ovarian cancer cell lines (PA1 and OVCAR3) at different concentrations. We found that mahanie content in the leaflet was more in the southern part of India during September–December, which is directly proportional to the highest medicinal values to elevate the commercial value of this high-demand plant.

### 2. Materials and Methods

#### 2.1. Cell Cultures.

Human ovarian (PA1 and OVCAR3), lung (A549), glioblastoma (U87MG), pancreatic (MIAPaCa-2), colorectal (HCT116), cervical (Hela), melanoma (Sk-mel-28), and osteosarcoma (MG-63) cancer cell lines were purchased from NCCS cell repository, Pune.

Additionally, melanoma (ChaMeli47), ovarian (SKOV3, OAW42, and UWB1.289+BRCa1), glioblastoma (U87MGVIII), and squamous oral (UPCI-SCC-084 and UPCI-SCC-131) carcinoma cell lines were kind gifts of Prof. Peter Walden, Charité-Universitätsmedizin, Berlin, Germany; Dr. SS Roy, CSIR-IICB; Dr. Frank Furnari, Ludwig Cancer Research Institute, US; Dr. Asima Mukhopadhyay, Tata Medical Center; and Dr. Susanta Roychoudhury, Saroj Gupta Cancer Center & Research Institute, Kolkata, respectively. All Cell lines were grown in complete medium (Table 1) supplemented with 10% FBS and 1% antibiotic-antimycotic at 37°C, 5% CO₂.

#### 2.2. Collection and Drying of Plant Material. "Murraya koenigii (L.) Spreng" belongs to the family Rutaceae (http://www.theplantlist.org) and is widely available all over India. Plant leaflets were procured throughout the year and also from east, west, north, south, and middle parts of India for three consecutive years. These were identified by Dr. Debrata Maity, Department of Botany, Kolkata, where a voucher specimen was deposited (20033(CUH)). These fresh leaflets (1.0 kg) were washed thoroughly with portable water followed by distilled water and dried in a dust-free environment. The dried leaflets (0.2 kg) were grinded into small pieces.

#### 2.3. Mahanie-Enriched Fraction (MEF).

Small pieces of dried leaflets (100 gram) were kept in distilled water (2.0 liters) at 50°C for four hours with stirring occasionally. The water portion was separated by filtration, and the remaining residue was dried (75 grams) for maceration with ethanol (1.5 liters) at ~30°C for 72 hours. This ethanolic fraction was dried. The yield of MEF from 100 g of dry leaf powder was calculated and stored at ~20°C in an airtight container.

#### 2.4. HPLC Analysis of MEF.

For quantification of markers by HPLC (Waters, 2487, Dual λ Absorbance UV Detector), MEF (500 μg/ml) was dissolved in methanol and water (80: 20) and filtered using 0.22 μm syringe filter. The RP-C18 column (5 μm, 250 × 4.6 mm, Waters, USA) was used. Sample (200 μl) was injected and run in an isocratic solvent system with 1.0 ml/minute flow rate. Peaks were monitored using a UV detector at 254 nm. All peaks area and retention time (RT, minutes) were calculated using Empower 2 software. Similarly, HPLC fingerprints of all MEFs including water extract were compared. The external calibration method was used to quantify the markers in MEF using pure compounds (5–20 μg) by HPLC [10].

#### 2.5. Isolation and Characterization of Markers.

MEF was packed on the silica column and eluted with petroleum ether and chloroform (100:0:0–100:100). Different fractions were monitored by TLC. Mahanie and mahanimbine fractions were separated by comparing with reference compounds which were previously isolated by our group [4]. Mahanie and mahanimbine were further purified by preparative TLC and HPLC using a reverse-phase C18 column to get ≥95% purity. Purification was confirmed by thin layer chromatography (TLC), high pressure liquid chromatography (HPLC), and mass spectrometry (ESI-Q TOF instrument), and the structure was confirmed by 1H Nuclear magnetic resonance (NMR) and 13C NMR (Bruker 600 MHz and JEOL 400 MHz instruments) [4]. Koenimbine-containing fraction
was washed thrice with methanol to yield pure compound and characterized similarly.

2.6. MTT Assay. MEF was dissolved in ethanol (10 mg/ml), and substocks were prepared with complete medium. The bioactivity of MEF, mahanine, mahanimbine, and koe-nimbine against cancer cell lines was determined separately by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. PA1 was harvested using trypsin and counted using the hemocytometer in the presence of trypan blue. Washed cells (4 × 10^3 in 250 μl/well) were placed in a 96-well plate and incubated for 1–2 hours. MEF (0–100 μg/ml) was added to each well in triplicates and incubated for 48 h at 37 °C. (Medium was discarded, and MTT (dissolved in IMDM, 100 μg/well) was added and incubated for 3 h at 37°C. Formazan crystals formed by the live cells were dissolved in DMSO. The intensity of the color was quantified at 550 nm in an ELISA plate reader, and IC50 values were calculated. Similarly, IC50 values were determined for all MEFs prepared from leaflets collected from various parts of India throughout the year. Additionally, IC50 values with other cell lines were also determined with MEF_TN (0–30 μg/ml).

Mahanine/mahanimbine in absolute ethanol and koe-nimbine in DMSO were taken to make 5000 μM stock for in vitro studies. Substocks were prepared with complete medium. PA1 and OVCAR3 were incubated separately with 0–100 μM of purified mahanine, mahanimbine, and koe-nimbine for 48 h and processed similarly.

2.7. In Vivo Xenograft Mice Model. MEF_TN (1.0 gram) was dissolved in ethanol (6.0 ml) diluted with sterile double distilled water (34 ml) to form a uniform suspension and used for oral feeding in mice. Before the initiation of the experiment, all mice were acclimated for 7 days and were kept five per group in individually ventilated cages (IVC) and used for in vivo efficacy studies. Female nude mice (4–6 weeks, n = 10) were injected subcutaneously with PA1 and A549 cells (7 × 10^6) separately. Tumors (∼100mm^3) were generated within 10–12 days. Animals were fed orally with MEF_TN (300 mg/kg BW) twice times per day for 31 days in ovarian and 14 days in lung cancer. Control/untreated animals were fed with vehicle (15% ethanol in water). The tumor size was monitored with screw gauge. Body weight during the treatment was also measured. This study has been approved by the institute’s ethical committee on animal experimentation.

2.8. Statistical Analysis. The data shown were representative of three sets of independent experiments. The results were represented as mean ± SD from independent experiments.

3. Results and Discussion

3.1. Enrichment of Mahanine in M. koenigii Extract. Our study for more than a decade established mahanine as a therapeutic lead molecule and may be considered as a main active principle in these leaflets. Here, we have used this carbazole alkaloid as the main stable reference marker.

| S. No. | Cancer type      | Cell lines | Mutation/drug-resistant | Culturing media + 10% FBS | MEF_TN IC50 (μg/ml) |
|-------|------------------|------------|-------------------------|---------------------------|--------------------|
| 1     | Ovarian          | PA1        | NRAS mutation anoikis-resistant | MEM                       | 15 ± 0.2           |
| 2     | Ovarian          | OVCAR3     | TP53 mutation drug-resistant | RPMI 1640                 | 27 ± 0.18          |
| 3     | Ovarian          | SKOV3      | TP53 mutation           | McCoy’s 5a                | 16.5 ± 0.11        |
| 4     | Ovarian          | OAW42      | ARID1A, PIK3CA mutation | DMEM                      | 15.5 ± 0.05        |
| 5     | Lung carcinoma   | UWB1.289 + BRCA1 | BRCA1 mutation             | MEM + RPMI 1640 (1:1)   | 25 ± 0.2           |
| 6     | Lung carcinoma   | A549       | KRS, CDKN2A mutation     | IMDDM                     | 13.0 ± 0.09        |
| 7     | Grade IV glioblastoma | U-87 MG | PTEN mutation           | IMDDM                     | 16.2 ± 0.15        |
| 8     | Grade IV glioblastoma | U87MG vili | EGFR mutation           | IMDDM                     | 18.7 ± 0.02        |
| 9     | Pancreatic carcinoma | MIA PaCa-2 | TP53, K-RAS mutation, p16 deletion | RPMI-1640                | 14.1 ± 0.1         |
| 10    | Colorectal       | HCT16      | KRAS, PIK3CA mutation   | IMDDM                     | 13.4 ± 0.4         |
| 11    | Cervical         | Hela       | STK11, CTNNB1, CTNT1 mutations | IMDDM                     | 15.45 ± 0.05       |
| 12    | Squamous cell oral carcinoma | UPCI-SCC084 | TP53 mutation           | DMEM                      | 14.5 ± 0.25        |
| 13    | Squamous cell oral carcinoma | UPCI-SCC131 | TP53 wild type           | DMEM                      | 15.5 ± 0.25        |
| 14    | Osteosarcoma     | MG63       | CDKN2A mutation         | MEM                       | 14.9 ± 0.22        |
| 15    | Melanoma         | ChaMel47   | No reports on mutation  | RPMI 1640                 | 18.5 ± 0.21        |
| 16    | Melanoma         | Sk-mel28   | B-RAF, TP53 mutation    | RPMI 1640                 | 19 ± 0.11          |
| 17    | Normal lung fibroblast cells | WI-38 | —                       | MEM                       | >80 ± 0.8          |

Antiproliferative activity of mahanine-enriched fraction prepared from Tamil Nadu leaflets (MEF_TN) was analyzed by the MTT assay. IC50 values and mutation status of all cancer cell lines were tabulated. These data were derived from three individual experiments, and mean ± SD was indicated.
However, isolation of the single molecules from the plant material is generally a multistep procedure which leads to low yield. More importantly, the majority of the plant-derived molecules are stereoisomers. The plant specifically synthesizes either levo (−) or dextro (+) isomer [11]. The activity of stereoisomers is not always the same; in fact, sometimes these are antagonistic [12]. Synthesis and purification of specific stereoisomers are difficult, time-taking, and costly process. Interestingly, plant-derived (−) mahanine is levo, which is a biologically active isomer. Even after two decades of the discovery of mahanine, the synthesis of this alkaloid is very difficult even today. Very recently, Hou et al. reported the synthesis of (±) mahanine involving eight steps with lesser yield [13]. This synthetic mahanine is expected to be less active as it is a mixture of two enantiomers. Therefore, isolation or synthesizing mahanine is commercially not viable.

Considering all these problems, here, we have prepared a mahanine-enriched fraction (MEF) using two edible non-toxic solvents, namely, water and ethanol, within a short time involving only two steps, which makes the final product cheaper and easy to commercialize. As mahanine is insoluble in water, clean leaflets collected from West Bengal during the September–December were extracted with hot water, and we discarded the water-soluble fraction. Next, maceration of the remaining leaflet residue with ethanol was performed. HPLC analysis of 25 µg of sample demonstrated (Figure 1(a)) that the ethanolic extract after removal of water-soluble fraction exhibited enhanced mahanine content (14%) (Table 2).

Each fraction was separately tested at different concentrations for its reduced metabolic activity against PA1 by the MTT assay. IC50 values were compared with the untreated control. Water extract exhibited very low/minimum activity (Table 2). The ethanolic extract, after removal of inactive water-soluble fraction, exhibited more reduction in metabolic activity, IC50 being 37 µg/ml. Therefore, this fraction is named as a mahanine-enriched fraction (MEF).

3.2. Isolation of Marker Compounds in MEF. The major problem for herbal medicine is the batch to batch variations of chemical compositions which adversely influence its biological activity [14]. To minimize these variations, we need to have a few well-characterized chemical markers for validating HPLC fingerprinting. For this purpose, we have identified three marker molecules, namely, mahanine, mahanimbine, and koenimbine from MEF. Previously, our group reported mahanine and mahanimbine from the methanolic extract of M. koenigii [4].

Here, we have isolated the mahanine and mahanimbine using the reference compounds, and purity was confirmed by HPLC (Figure S1). ESI–MS (Figure S2), 1H (Figure S3), and 13C NMR spectral data analyses established their structures as mahanine and mahanimbine (Figure 1(b)). During this process, we have also isolated another carbazole alkaloid, koenimbine, and characterization was again confirmed by HPLC, ESI-MS, NMR, and compared with the available literature (PubChem CID: 97487). The calibration curves for all three molecules were plotted with three different concentrations (5, 10, and 20 µg) for further studies (Figure S4; Table S1).

3.3. Biological Activity of Three Carbazole Alkaloids Isolated from MEF against Ovarian Cancer Cells. We have earlier compared the degree of apoptosis between mahanine and mahanimbine in lymphoblastic leukemia, myeloid leukemia, glioma, pancreatic, lung, colorectal, and cervical cancers cells [4]. Koenimbine reduced metabolic activity of prostate cancer [15], breast cancer [16], and liver cancer cells [17]. However, the biological activity of mahanimbine and koenimbine was not tested in ovarian cancer cells. In our previous studies, we have tested mahanine-induced cell death by the MTT assay [8]. These results were corroborated with many other methods indicating reduced cell viability, i.e., apoptosis [8]. Therefore, reduced metabolic activity may indicate the antiproliferative property.

Here, we have compared the antiproliferative activity of all three carbazole alkaloids at different concentrations (0–100 µM) both in PA1 and a cisplatin-resistant (OVCAR3) ovarian cancer cells by the MTT assay (Figures 2(a) and 2(b)). All these molecules induce cell death in a concentration-dependent manner. Mahanine exhibited the highest activity against PA1 and OVCAR3 compared to others under identical conditions (Table 3).

3.4. Seasonal Variations of Mahanine. Our next aim was to select the best season for collection of leaflets with a high quantity of mahanine for MEF preparation. Initially, we have collected leaflets from West Bengal for every two months throughout the year for three consecutive years. MEF was prepared (MEFWB) for each batch, and mahanine content was analyzed by HPLC. The highest amount of mahanine was present in leaflets collected during September to December (14 ± 1.5%), which drops to a minimum during January–April (≦5%) and medium (≦6–10%) during May–August (Table 4, Figures 3(a) and 3(b)). However, the percent of mahanimbine and koenimbine was 9–20% and 8–15%, respectively. A minimum amount of koenimbine was observed from May to July. A similar trend was observed in three years.

The IC50 of all MEFs was tested with different concentrations and compared against PA1 (Table 4). The IC50 of MEF from the leaflets collected during September–December was highest corroborating with a higher content of mahanine suggesting the best time for collection.

3.5. Variation of Mahanine in the Leaflets Collected from Different Geographical Locations. Chemical composition/active principle of the plant varies from place to place in a wide range from 0.9 to 100 [18]. The medicinal value of a plant is directly proportional to the quantity of biologically active principles. Mahanine is the most active carbazole alkaloid found in M. koenigii.

To standardize the place, we have collected leaflets from nine different regions covering all parts of India from September to December in three consecutive years. The
plant material was authenticated by DNA bar-coding as reported earlier [19]. Leaflets of different regions varied in their shape, size, thickness, color (dark/light green), and odor (Figure 4(a)). The yield (gram of MEF/100 g of the dry leaf) varied from 5.5% to 9.0%, Tamil Nadu being the highest. Interestingly, the percent of mahanine varied in a wide range.

![HPLC profile of MEFWB and structures of identified markers](image)

**Figure 1:** (a) HPLC profile of MEF<sub>WB</sub> and structures of identified markers. The arrows indicate the peaks corresponding to the three isolated markers matched with their retention times in the HPLC profile of MEF<sub>WB</sub>. (b) Chemical structures of three carbazole alkaloids isolated from MEF<sub>WB</sub> used as markers.

**Table 2:** Preparation of MEF form *M. koenigii* leaflets from West Bengal.

| Extract                                | Mahanine (%) | IC50 (µg/ml) |
|----------------------------------------|--------------|--------------|
| Water extract                          | 0            | 90           |
| Mahanine-enriched fraction (MEF<sub>WB</sub>) | 14          | 37           |

Comparison of the water extract and MEF<sub>WB</sub> for their mahanine content and biological activity against PA1. IC50: the half-maximal inhibitory concentration.

![Antiproliferative activities of mahanine, mahanimbine, and koenimbine isolated from MEF<sub>WB</sub> against ovarian cancer as determined by the MTT assay](image)

**Figure 2:** Antiproliferative activities of mahanine, mahanimbine, and koenimbine isolated from MEF<sub>WB</sub> against ovarian cancer as determined by the MTT assay (a, b). Ovarian cancers cells were exposed to varying concentrations of purified mahanine, mahanimbine, and koenimbine separately for 48 h. IC50 was calculated as the percentage relative to untreated cells which were considered as 100%. Antiproliferative activity of mahanine against PA1 and OVCAR3 by MTT assay has earlier been reported [8]; here, we have repeated this experiment for comparison with mahanimbine and koenimbine. These data were derived from three individual experiments, and mean ± SD was indicated.
The amount of mahanine (Figures 4(b) and 4(c)) is highest in Tamil Nadu (MEFTN; ∼43 ± 2.5%). However, the percent of mahanimbine (∼8.3%) and koenimbine (∼0.8%) in MEFTN was significantly low. The percent of these two alkaloids differs from place to place. In most of the places, the percent of koenimbine is either low or sometimes not even detectable. HPLC fingerprint of MEF, prepared from all these leaflets, is also different (Figure 5). The percent of alkaloids present in the leaflets collected during three years did not vary significantly.

The content of mahanine in the majority of the places, Jammu (MEFJ), being the highest. It is worthwhile to mention that these two molecules just differed with a hydroxyl group (−OH) at C7 position. We have earlier demonstrated the structure-activity relationship of these two alkaloids and confirmed that −OH group is crucial for its antiproliferative effect against cancer cells [4].

The highest yield of MEF and amount of mahanine in these leaflets depends on various factors including temperature, rainfall, and sunshine in this Torrid Zone. In summary, the best place for collecting leaflets with the highest quantity of mahanine is southern part (tropical zone), Tamil Nadu (MEFTN). Our data proved that selection of the place for collection of plant material is an essential component for preparing any extract/fraction with the highest medicinal property.

**Table 3:** Reduced metabolic activity by three carbazole alkaloids from MEF against ovarian cancer.

| Ovarian cancer cell lines | Mahanine (μM) | Mahanimbine (μM) | Koenimbine (μM) | IC50 (μM) |
|---------------------------|---------------|-----------------|-----------------|-----------|
| PA1                       | 11 ± 0.2      | 28 ± 0.11       | 51 ± 0.25       |           |
| OVCAR3                    | 32 ± 0.18     | 52 ± 0.05       | 68 ± 0.22       |           |

Cells were treated separately with mahanimbine and koenimbine for 48 h, and mahanine was used as the control for comparison [8]. IC50 values were compared. These data were derived from three individual experiments, and mean ± SD was indicated.

**Table 4:** Seasonal variation of three markers and antiproliferative activity of MEFWB.

| The month of collection of leaflets | Mahanine (%) | Mahanimbine (%) | Koenimbine (%) | MEFWB IC50 (μg/ml) |
|------------------------------------|--------------|-----------------|---------------|--------------------|
| February                           | 5 ± 1.5      | 12 ± 1.4        | 15 ± 1.8      | 73.2 ± 0.15        |
| April                              | 5 ± 1.9      | 11 ± 1.8        | 12 ± 1.2      | 71.0 ± 0.5         |
| May                                | 6 ± 1.7      | 9 ± 1.5         | 8 ± 0.9       | 68.0 ± 0.14        |
| July                               | 9 ± 1.6      | 16 ± 1.2        | 8 ± 1.5       | 55.0 ± 0.3         |
| September                          | 12 ± 1.8     | 18 ± 1.6        | 10 ± 1.1      | 39.0 ± 0.3         |
| December                           | 14 ± 1.5     | 20 ± 1.6        | 11 ± 1.25     | 37.0 ± 0.2         |

Composition of markers in MEFWB in different seasons and their IC50. These are representative data collected in one year. MEFWB: mahanine-enriched fraction prepared from West Bengal leaflets. These data were derived from three individual experiments, and mean ± SD was indicated.

**Figure 3:** Seasonal variation of mahanine in MEFWB. (a) MEFWB prepared from the leaflets collected during different seasons was analyzed by HPLC. The variations in percent of mahanine were plotted on the graph. (b) Schematic representation of seasonal variations of mahanine from low to high. These data were derived from three individual experiments, and mean ± SD was indicated.
3.6. Correlation of Mahanine Content and Antiproliferative Activity of MEFs. The MEF prepared from leaflets collected from different regions of India during September–December was checked for their biological activity against PA1 with various concentrations. IC50 varied from ∼15 to ∼75 μg/ml, indicating ∼5 fold reduced biological activity of MEF_{TN} compared to MEF_{B} corroborating with the highest percent of mahanine (Figure 4(d)).

Statistical evaluation of these results by the “Spearman-rank” correlation method showed 0.97 (97.6%) which confirms the significance of the positive correlation between mahanine content in the leaflets and its biological activity against cancer cells. Therefore, the medicinal values of the plant are directly proportional to the mahanine content.

Although other two markers (mahanimbine and koenimbine) showed reduced metabolic activity separately, they present in minute amount, respectively, in MEF_{TN} (Table 5) is compared to biologically more active mahanine (∼43%). Due to the low concentration of mahanimbine and koenimbine, they may not contribute significantly to the total activity of MEF_{TN}. 

**Figure 4**: Geographical variations of mahanine, mahanimbine, and koenimbine and its relation with antiproliferative activity. (a) Morphological differences in leaflets collected from nine different locations. (b) Locations for leaflets collection were marked on the map; highlights with black, green, and red dots represent the low, medium, and high quantities of mahanine. (c) The percent of mahanine in MEFs prepared from different places. (d) IC50 values of MEFs were checked for their activity against PA1 for 48 h by the MTT assay. These results were compared with mahanine quantity as depicted in Figure 4(d). These data were derived from three individual experiments, and mean ± SD was indicated.
Table 5: Regional variation of mahanine, mahanimbine, and koenimbine in different MEFs.

| Region of leaf collection | Yield: a gram of MEF/100 g of dry leaf | Mahanine (%) | Mahanimbine (%) | Koenimbine (%) |
|---------------------------|----------------------------------------|--------------|-----------------|---------------|
| Jammu (MEF_J)             | 6.4 ± 0.5                              | 9.3 ± 1.6    | 27.0 ± 2.5      | 6.3 ± 1.2     |
| Bihar (MEF_B)             | 5.8 ± 0.2                              | 2.7 ± 1.3    | 12.0 ± 1.5      | 7.3 ± 1.4     |
| Madhya Pradesh (MEF_MP)   | 7.2 ± 0.1                              | 5.0 ± 0.9    | 8.6 ± 0.9       | 1.2 ± 0.9     |
| West Bengal (MEF_WB)      | 5.5 ± 0.5                              | 14.0 ± 0.8   | 20.7 ± 1.2      | 11.9 ± 1.1    |
| Goa (MEF_G)               | 6.5 ± 0.6                              | 33.0 ± 2.9   | 6.3 ± 0.9       | 7.3 ± 1.4     |
| Maharashtra (MEF_M)       | 5.9 ± 0.1                              | 34.0 ± 2.7   | 10.0 ± 1.1      | ND            |
| Andhra Pradesh (MEF_AP)   | 5.9 ± 0.25                             | 23.0 ± 4.1   | 9.2 ± 0.9       | ND            |
| Tamil Nadu (MEF_TN)       | 9.0 ± 0.7                              | 43.0 ± 2.5   | 8.3 ± 1.7       | 0.8 ± 0.3     |
| Kerala (MEF_K)            | 8.0 ± 0.5                              | 35 ± 4.0     | 6.3 ± 1.2       | ND            |

The yield of all MEFs (mahanine-enriched fractions) and their markers as obtained from HPLC. ND: not detected. A representative profile of these alkaloids in leaflet collected during one year has been tabulated. These data were derived from three individual experiments, and mean ± SD was indicated.

Figure 5: HPLC fingerprints all MEFs, showing the geographical variations of three markers. HPLC profiles of MEFs from leaflets were marked for mahanine, mahanimbine, and koenimbine with their respective retention times (RTs) for comparison.
Since mahanine content is more in MEFTN, we have compared the percent of this alkaloid in the leaflets collected from ten different regions within the Tamil Nadu during different seasons. As expected, mahanine content is more from September to December. Leaflets from all ten places showed a good amount of mahanine varying from 35 to 45%. IC50 of MEF from these leaflets was in the range of 15–20 μg/ml. Here, also we confirmed that the activity of MEF depends upon the percent of the mahanine present in these leaflets.

3.7. In Vitro Activity of MEF against Various Cancer Cell Lines of Different Origins. So far, our results demonstrated that both the mahanine content and biological activity are highest in MEFTN. Next, this (0–60 μg/ml) was tested against sixteen cancer cell lines with different mutations and chemoresistant status belonging to nine different cancers. MEF reduced the metabolic activity in all these cell lines in a concentration-dependent manner. IC50 values were in the range of ~13.2–19.0 μg/ml in ovarian, lung, Grade IV glioblastoma, melanoma, pancreatic, colorectal, cervical, osteosarcoma, and oral cancers (Table 1). MEFTN (0–150 μg/ml) was tested against normal lung fibroblast cells, IC50 being ~80 μg/ml. This result demonstrates the potentiality of MEF as a broad antiproliferative agent in many different cancers with various mutations at low concentration.

Additionally, we observed that except OVCAR3 and UWBI.289+BRCA1, all other cells exhibited IC50 < 20 μg/ml of MEFTN. OVCAR3 cells are reported to be resistant to cisplatin, Adriamycin, and melphalan [20]. UWBI.289 +BRCA1 cells having BRCA1 mutation is resistant to PARP inhibitor drugs like rucaparib, olaparib, and veliparib [21]. Due to these inherent drug-resistance properties, these two cell lines showed higher IC50 values compared to others.

3.8. Efficacy of MEFTN in Ovarian and Lung Cancer Xenograft Models. To check the in vivo efficacy of MEFTN, we have used two representative ovarian and lung cancers models. MEFTN-treated mice (300 mg/kg BW p.o. BID) showed reduction in tumor size from ~354 to 89 mm³ in ovarian cancer compared to the untreated animals (Figures 6(a) and 6(b) and Table 6). No weight loss was observed in MEF-treated tumor-bearing mice up to 31 days indicating no apparent toxicity in other organs (Figure 6(c)). Similarly, MEFTN-treated animal exhibited a reduced tumor mass from ~426 to 170 mm³ in lung cancer model (Figures 6(d) and 6(e)).
4. Conclusions

We are reporting a mahanine-enriched fraction (MEF) prepared using two nontoxic edible solvents in two steps. Three carbazole alkaloids, namely, mahanine, mahanimbine, and koenimbine, have been isolated and characterized. This is the first report showing reduced metabolic activity of mahanimbine and koenimbine in ovarian cancer cells in a concentration-dependent manner. Our systematic study (Figure 7) reveals that the percent of mahanine is highest in leaflets collected from Tamil Nadu (MEF\textsubscript{TN}) from September to December. MEF\textsubscript{TN} exhibited the highest activity against cancer cells. Thus, the medicinal values of this plant are directly proportional to the amount of mahanine present in the leaflets. Most importantly, MEF\textsubscript{TN} significantly reduces tumor mass both in ovarian and lung cancer xenograft models. Taken together, this study suggests that we can improve the medicinal property of this high-value plant to ~5 fold by right selection of season and place for leaf collection. MEF\textsubscript{TN} also showed reduced metabolic activity in sixteen cell lines from nine different origins in a concentration-dependent manner. To the best of our knowledge, this is the first report demonstrating variations of mahanine, mahanimbine, and koenimbine in this important herb collected during different seasons from various locations of India reflected in their medicinal values. Such a study is expected to increase the commercial values of this medicinal plant and enhance the efficacy of phytopharmaceuticals prepared from this herb.

**Abbreviations**

| Abbreviations | Definition |
|---------------|------------|
| OC            | Ovarian cancer |
| MEF           | Mahanine-enriched fraction |
| MEF\textsubscript{WB} | MEF from West Bengal leaflets |
| MEF\textsubscript{TN} | MEF from Tamil Nadu leaflets |
| MEF\textsubscript{B} | MEF from Bihar leaflets |
| IC50          | The half-maximal inhibitory concentration |
| BW            | Bodyweight |
| MTT           | 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
| FBS           | Fetal bovine serum |
| p.o.          | Per os (oral administration) |
| BID           | Bis in die (twice daily) |

**Data Availability**

No data were used to support this study.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Acknowledgments**

E. M. Satyavarapu and P. K. Sinha sincerely acknowledge the fellowship from CSIR. This study was supported by CSIR (HCP0010), ICMR (GAP 370), Department of Biotechnology (DBT, GAP 346), and SERB (GAP 336 and GAP 337).
nimbine: 1H NMR (600 MHz, chloroform-δ) 1.7 Hz, 3H), 1.57 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 2.32 (d, J = 8.7 Hz, 2.5 Hz, 1H), 6.57 (d, J = 9.7 Hz, 1H), 5.66 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 2.32 (d, J = 0.9 Hz, 3H), 1.48 (s, 6H). All these NMR’s were matched with the available literature (PubChem CID: 375151, 167963, and 97487, respectively). Figure S4: (calibration curves of mahanine, mahanimbine, and koenimbine by 1H NMR. Mahanine: 1H NMR (400 MHz, Methanol-δ) δ 7.62 (d, J = 7.7 Hz), 7.52, 7.45, 6.77, 6.58, 5.64–5.57 (m), 5.08, 3.28, 2.24, 2.12 (d, J = 6.2 Hz), 1.67 (d, J = 9.5 Hz), 1.60, 1.53, 1.37. Mahanimbine: 1H NMR (600 MHz, chloroform-δ) δ 7.89 (d, J = 6.0 Hz, 1H), 7.82 (s, 1H), 7.64 (s, 1H), 7.31–7.26 (m, 2H), 7.16 (ddd, J = 6.0 Hz, 1H), 6.54 (d, J = 6.0 Hz, 1H), 5.58 (d, J = 6.0 Hz, 1H), 5.10 (ddt, J = 6.0 Hz, 1H), 2.32 (d, J = 6.0 Hz, 3H), 2.23–2.10 (m, 3H), 1.74 (dd, J = 9.3, 7.4 Hz, 2H), 1.65 (d, J = 1.7 Hz, 3H), 1.57 (d, J = 1.6 Hz, 3H), 1.42 (s, 3H). Koenimbine: 1H NMR (600 MHz, chloroform-δ) δ 7.72 (s, 1H), 7.62 (s, 1H), 7.40 (d, J = 2.5 Hz, 1H), 7.25 (d, J = 1.3 Hz, 1H), 6.93 (dd, J = 8.7, 2.5 Hz, 1H), 6.57 (d, J = 9.7 Hz, 1H), 5.66 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 2.32 (d, J = 0.9 Hz, 3H), 1.48 (s, 6H). All these NMR’s were matched with the available literature (PubChem CID: 375151, 167963, and 97487, respectively). Figure S4: (calibration curves of mahanine, mahanimbine, and koenimbine) all three carbazole alkaloids were dissolved separately in methanol:water (80:20) and filtered for HPLC analysis. Each molecule was injected separately in three different concentrations (5, 10, and 20 μg). Area vs. concentration was plotted. This calibration curve was used to calculate the amount of these markers in different MEFs. Table S1: the obtained area of each concentration for the respective molecule from Figure S4 was tabulated to calculate the amount of all three markers in different MEF’s. (Supplementary Materials)

References

[1] M. S. Valiathan, The Legacy of Caraka, Orient Longman Publishers, Hyderabad, India, 2003.
[2] S. Mondal, S. Bandyopadhyay, M. K. Ghosh, S. Mukhopadhyay, S. Roy, and C. Mandal, “Natural products: promising resources for cancer drug discovery,” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 1, pp. 49–75, 2012.
[3] W. Liu, J. Liu, D. Yin, and X. Zhao, “Influence of ecological factors on the production of active substances in the anticancer plant Sinopodophyllum hexandrum (Royle) T. S. Ying,” PlOS one, vol. 10, no. 4, Article ID 0122981, 2015.
[4] S. K. Samanta, D. Dutta, S. Roy et al., “Mahanine, a DNA minor groove binding agent exerts cellular cytotoxicity with involvement of C-7-OH and –NH functional groups,” Journal of Medicinal Chemistry, vol. 56, no. 14, pp. 5709–5721, 2013.
[5] K. Bhattacharya, S. Maiti, and C. Mandal, “PTEN negatively regulates mTORC2 formation and signaling in grade IV gloma via Rictor hyperphosphorylation at Thr135 and direct the mode of action of an mTORC1/2 inhibitor,” Oncogenesis, vol. 5, no. 5, p. e2277, 2016.
[6] S. Maiti, S. Mondal, E. M. Satyavaramu, and C. Mandal, “mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation,” Cell Death & Disease, vol. 8, no. 7, Article ID e2926, 2017.
[7] S. Sarkar, D. Dutta, S. K. Samanta et al., “Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo,” International Journal of Cancer, vol. 132, no. 3, pp. 695–706, 2013.
[8] E. M. Satyavaramu, R. Das, C. Mandal, A. Mukhopadhyay, and C. Mandal, “Autophagy-independent induction of LC3B through oxidative stress reveals its non-canonical role in anoikis of ovarian cancer cells,” Cell Death & Disease, vol. 9, no. 10, p. 934, 2018.
[9] S. Roy, D. Dutta, E. M. Satyavaramu et al., “Mahanine exerts in vitro and in vivo antileishmanial activity by modulation of redox homeostasis,” Scientific Reports, vol. 7, no. 1, p. 4141, 2017.
[10] B. Dhandapani, M. S. Eswaran, N. Susrutha et al., “Spectrophotometric estimation of meloxicam in bulk and its pharmaceutical formulations,” International Journal of Pharma Sciences and Research (IJPASR), vol. 1, pp. 217–221, 2010.
[11] M. F. Jennifer, D. H. Sherman, K. Martin, and M. W. Robert, “Enantiomeric natural products: occurrence and biogenesis,” Angewandte Chemie International Edition, vol. 51, no. 20, pp. 4802–4836, 2012.
[12] S. W. Smith, “Chiral toxicology: it’s the same thing...Only different,” Toxicological Sciences, vol. 110, no. 1, pp. 4–30, 2009.
[13] S. Hou, Y. Liu, Y. Kong, and M. L. Brown, “Total synthesis of 7-hydroxymurrayazolinine, murrayamine D, and mahanine via m-nitro group activated pyran annulation,” Organic Letters, vol. 17, no. 10, pp. 2298–2301, 2015.
[14] J. Zhang, B. Wider, H. Shang, X. Li, and E. Ernst, “Quality of herbal medicines: challenges and solutions,” Complementary Therapies in Medicine, vol. 20, no. 1-2, pp. 100–106, 2012.
[15] B. Kamasilehghian, S. Ghafoouri-Fard, E. Motveaseli, and F. Ahmadipour, “Inhibition of human prostate cancer (PC-3) cells and targeting of PC-3-derived prostate cancer stem cells with koenimbine, a natural dietary compound from Murraya koenigii (L) Spreng,” Drug Design, Development and Therapy, vol. 12, pp. 1119–1133, 2018.
[16] F. Ahmadipour, M. I. Noordin, S. Mohan et al., “Koenimbine, a natural dietary compound of Murraya koenigii (L) Spreng; inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44+/CD24−/low): an in vitro study,” Drug Design, Development and Therapy, vol. 9, pp. 1193–1208, 2015.
[17] Y. H. Hobs, “The role of oxidative stress in koenimbine-induced DNA damage and heat shock protein modulation in HepG2 cells,” Integrative Cancer Therapies, vol. 16, no. 4, pp. 563–571, 2017.
[18] R. S. Sangwan, N. D. Chaurasiya, L. N. Misra et al., "Phytochemical variability in commercial herbal products and preparations of Withania somnifera (Ashwagandha)," Current Science, vol. 86, pp. 461–465, 2004.

[19] S. L. Vassou, S. Nithaniyal, B. Raju, and M. Parani, "Creation of reference DNA barcode library and authentication of medicinal plant raw drugs used in Ayurvedic medicine," BMC Complementary and Alternative Medicine, vol. 16, no. S1, p. 186, 2016.

[20] T. C. Hamilton, R. C. Young, W. M. McKoy et al., "Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors," Cancer Research, vol. 43, pp. 5379–5389, 1983.

[21] Y. E. Choi, K. Meghani, M. E. Brault et al., "Platinum and PARP inhibitor resistance due to overexpression of Micro-RNA-622 in BRCA1 -mutant ovarian cancer," Cell Reports, vol. 14, no. 3, pp. 429–439, 2016.